Compare First Horizon Corporation Common Stock (FHN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Gilead Sciences, Inc. — how do they compare? First Horizon Corporation Common Stock trades at $21.88 (market cap $10.74B), while Gilead Sciences, Inc. trades at $155.87 (market cap $190.38B). The key difference: Gilead Sciences, Inc. is far larger — about 17.7× First Horizon Corporation Common Stock's market cap, and First Horizon Corporation Common Stock pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Gilead Sciences, Inc. for 112 Days on average.
| FHN | GILD | |
|---|---|---|
Market Cap | $10.74B | $190.38B |
Volume | 11,773,440 | 5,758,183 |
Sector | Financials | Health |
52-Week High | $26.23 | $155.80 |
52-Week Low | $19.94 | $117.85 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $14.03B | $213.45B |
Dividend Yield | 3% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $153.13. Recent earnings beat expectations in three consecutive quarters, though Q3 2026 results are pending. The company maintains strong operating cash flow of $10.02B in 2025 and has expanded HIV prevention access through a new PAHO partnership in Latin America.
Investment outlook remains positive with 67% analyst buy ratings and potential upside to price targets, though risks include negative net income margin (-10.64%) projected for 2026 and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, but investors should monitor earnings sustainability and pipeline developments in oncology and HIV therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
